annual EBITDA:
-$154.53M+$340.60M(+68.79%)Summary
- As of today (July 1, 2025), APLS annual EBITDA is -$154.53 million, with the most recent change of +$340.60 million (+68.79%) on December 31, 2024.
- During the last 3 years, APLS annual EBITDA has risen by +$576.74 million (+78.87%).
- APLS annual EBITDA is now -3740.83% below its all-time high of -$4.02 million, reached on December 31, 2013.
Performance
APLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$80.39M-$56.31M(-233.86%)Summary
- As of today (July 1, 2025), APLS quarterly EBITDA is -$80.39 million, with the most recent change of -$56.31 million (-233.86%) on March 31, 2025.
- Over the past year, APLS quarterly EBITDA has dropped by -$21.55 million (-36.62%).
- APLS quarterly EBITDA is now -189.32% below its all-time high of $90.00 million, reached on December 31, 2020.
Performance
APLS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$176.07M-$21.55M(-13.94%)Summary
- As of today (July 1, 2025), APLS TTM EBITDA is -$176.07 million, with the most recent change of -$21.55 million (-13.94%) on March 31, 2025.
- Over the past year, APLS TTM EBITDA has increased by +$208.33 million (+54.20%).
- APLS TTM EBITDA is now -6501.95% below its all-time high of -$2.67 million, reached on September 30, 2014.
Performance
APLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.8% | -36.6% | +54.2% |
| 3 y3 years | +78.9% | +37.6% | +74.2% |
| 5 y5 years | +48.3% | +51.2% | +61.3% |
APLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +78.9% | -233.9% | +56.0% | -13.9% | +73.2% |
| 5 y | 5-year | at high | +78.9% | -189.3% | +62.6% | -13.9% | +75.9% |
| alltime | all time | -3740.8% | +78.9% | -189.3% | +62.6% | -6501.9% | +75.9% |
APLS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$80.39M(+233.9%) | -$176.07M(+13.9%) |
| Dec 2024 | -$154.53M(-68.8%) | -$24.08M(-44.9%) | -$154.53M(-26.3%) |
| Sep 2024 | - | -$43.70M(+56.6%) | -$209.63M(-29.7%) |
| Jun 2024 | - | -$27.91M(-52.6%) | -$298.22M(-22.4%) |
| Mar 2024 | - | -$58.84M(-25.7%) | -$384.40M(-22.4%) |
| Dec 2023 | -$495.13M(-19.8%) | -$79.18M(-40.1%) | -$495.13M(-13.9%) |
| Sep 2023 | - | -$132.29M(+15.9%) | -$575.18M(-8.0%) |
| Jun 2023 | - | -$114.09M(-32.7%) | -$625.45M(-5.0%) |
| Mar 2023 | - | -$169.57M(+6.5%) | -$658.06M(+6.6%) |
| Dec 2022 | -$617.33M(-15.6%) | -$159.23M(-12.8%) | -$617.32M(+2.5%) |
| Sep 2022 | - | -$182.56M(+24.4%) | -$602.28M(-1.7%) |
| Jun 2022 | - | -$146.70M(+13.9%) | -$612.73M(-10.0%) |
| Mar 2022 | - | -$128.83M(-10.7%) | -$681.01M(-6.9%) |
| Dec 2021 | -$731.27M(+134.2%) | -$144.19M(-25.3%) | -$731.27M(+47.1%) |
| Sep 2021 | - | -$193.01M(-10.2%) | -$497.08M(+15.6%) |
| Jun 2021 | - | -$214.98M(+20.0%) | -$429.95M(+31.7%) |
| Mar 2021 | - | -$179.09M(-299.0%) | -$326.56M(+4.6%) |
| Dec 2020 | -$312.23M | $90.00M(-171.5%) | -$312.23M(-38.9%) |
| Sep 2020 | - | -$125.89M(+12.8%) | -$511.30M(+12.5%) |
| Jun 2020 | - | -$111.59M(-32.3%) | -$454.50M(+9.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$164.76M(+51.1%) | -$413.72M(+38.4%) |
| Dec 2019 | -$298.83M(+139.1%) | -$109.07M(+57.9%) | -$298.83M(+32.6%) |
| Sep 2019 | - | -$69.08M(-2.4%) | -$225.40M(+17.8%) |
| Jun 2019 | - | -$70.81M(+42.0%) | -$191.29M(+24.9%) |
| Mar 2019 | - | -$49.87M(+39.9%) | -$153.21M(+23.1%) |
| Dec 2018 | -$124.99M(+146.9%) | -$35.64M(+1.9%) | -$124.41M(+16.7%) |
| Sep 2018 | - | -$34.97M(+6.8%) | -$106.63M(+28.1%) |
| Jun 2018 | - | -$32.73M(+55.3%) | -$83.25M(+32.9%) |
| Mar 2018 | - | -$21.07M(+18.0%) | -$62.65M(+23.7%) |
| Dec 2017 | -$50.63M(+86.7%) | -$17.86M(+54.1%) | -$50.63M(+28.8%) |
| Sep 2017 | - | -$11.59M(-4.5%) | -$39.30M(+12.5%) |
| Jun 2017 | - | -$12.13M(+34.0%) | -$34.94M(+53.2%) |
| Mar 2017 | - | -$9.05M(+38.8%) | -$22.81M(+65.8%) |
| Dec 2016 | -$27.12M(+35.0%) | -$6.52M(-9.9%) | -$13.76M(-3.1%) |
| Sep 2016 | - | -$7.23M(+3.9%) | -$14.20M(+17.1%) |
| Dec 2015 | -$20.09M(+78.0%) | -$6.96M(+35.0%) | -$12.12M(+50.2%) |
| Sep 2015 | - | -$5.16M(+77.0%) | -$8.07M(+44.6%) |
| Dec 2014 | -$11.29M(+180.6%) | -$2.91M(+9.3%) | -$5.58M(+109.3%) |
| Sep 2014 | - | -$2.67M | -$2.67M |
| Dec 2013 | -$4.02M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual EBITDA year-on-year change?
- What is Apellis Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Apellis Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?
What is Apellis Pharmaceuticals annual EBITDA?
The current annual EBITDA of APLS is -$154.53M
What is the all time high annual EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual EBITDA is -$4.02M
What is Apellis Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, APLS annual EBITDA has changed by +$340.60M (+68.79%)
What is Apellis Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of APLS is -$80.39M
What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly EBITDA is $90.00M
What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, APLS quarterly EBITDA has changed by -$21.55M (-36.62%)
What is Apellis Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of APLS is -$176.07M
What is the all time high TTM EBITDA for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM EBITDA is -$2.67M
What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, APLS TTM EBITDA has changed by +$208.33M (+54.20%)